Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs

Elanco Animal Health dropped its 2025 Impact Report this week, and buried under the usual corporate-report packaging is a genuinely useful snapshot of where the animal health industry is headed, and what that means for the people writing prescriptions and running wellness exams every day.

The headline number is $892 million in 2025 revenue generated from products that did not exist a few years ago, led by Credelio Quattro, Zenrelia, Experior, and AdTab. Credelio Quattro is now Elanco's fastest-growing pet health product to date and one of the fastest launches the animal health sector has seen. Zenrelia, the company's newer dermatology option, has reportedly reached more than two million dogs with chronic itch. For clinics fielding daily calls about allergy season, that is not an abstract figure, it is a real shift in what is sitting on the pharmacy shelf.

Elanco is also positioning itself for what comes next. The report outlines a pipeline of five to six blockbuster-potential approvals expected by 2031, with a combined peak sales estimate north of $2 billion, roughly double the value of the company's last innovation wave. Part of that pipeline includes emergency and conditional authorizations aimed at New World screwworm, a resurgent parasitic threat to livestock and companion animals that has been drawing increasing attention from practitioners in affected regions.

“Animals are at the center of two of society's most fundamental needs.” — Jeff Simmons, President and CEO, Elanco

That line from CEO Jeff Simmons is doing a lot of work in the report, and it is worth sitting with. The pitch is that companion animal medicine and food-animal production are no longer separate conversations happening in separate corners of the industry, they are two expressions of the same underlying demand, and Elanco is trying to build a business model that serves both without treating either as secondary.

The sustainability numbers back that framing up. Elanco says it helped feedyards quantify and monetize carbon-reduction work across more than 1.4 million cattle in 2025, translating to more than 200,000 metric tons of CO2 equivalent reductions, using tools like Bovaer, Experior, and Rumensin. On the food safety side, the company points to a Salmonella control program now running in 23 countries and a counterfeit-product recovery effort that pulled more than 160,000 fake products worth over $13 million out of circulation, a reminder that supply chain integrity is still very much a live issue in animal health.

There is also a workforce and wellbeing thread running through the report that will land differently depending on where you sit in the profession. Elanco cites continued investment in veterinarian mental health resources, professional education, and academic partnerships, alongside internal numbers like a 73 percent employee engagement score and more than 28,000 employee volunteer hours logged in 2025. The company also opened a new global headquarters anchoring a One Health Innovation District built in partnership with Purdue University, explicitly framed around collaboration across animal, human, and plant health rather than siloed research.

None of this erases the fact that Elanco is, at the end of the day, a public company reporting to shareholders, and impact reports are inherently a bit of a highlight reel. But the through line here, tying new drug launches to livestock sustainability data to veterinarian burnout resources, is a fairly accurate reflection of what the job actually looks like right now for a lot of practitioners: clinical work, production agriculture pressure, and workforce strain, all pulling on the same person some days.

The full 2025 Elanco Impact Report and accompanying ESG disclosures are available directly from Elanco for anyone who wants to dig into the underlying data.